Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to shrink head and neck tumors before surgery

NCT ID NCT07457281

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated Jun 19, 2026 · Updated 7 times

Summary

This early-phase study tests whether combining two drugs (GV20-0251 and sintilimab) before surgery is safe and can shrink tumors in adults with a type of head and neck cancer. Nine participants will receive two cycles of the drug combo, then have surgery. The main goals are to check for side effects and see how many tumors respond. This is not a cure, but aims to control the disease before and after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC